These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17493584)

  • 1. Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos.
    Morcos PA
    Biochem Biophys Res Commun; 2007 Jun; 358(2):521-7. PubMed ID: 17493584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of pre-mRNA splicing by antisense oligonucleotides.
    Taylor JK; Dean NM
    Curr Opin Drug Discov Devel; 1999 Mar; 2(2):147-51. PubMed ID: 19649941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L30 binds the nascent RPL30 transcript to repress U2 snRNP recruitment.
    Macías S; Bragulat M; Tardiff DF; Vilardell J
    Mol Cell; 2008 Jun; 30(6):732-42. PubMed ID: 18570876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.
    Resina S; Kole R; Travo A; Lebleu B; Thierry AR
    J Gene Med; 2007 Jun; 9(6):498-510. PubMed ID: 17471591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted pre-mRNA modification for gene silencing and regulation.
    Zhao X; Yu YT
    Nat Methods; 2008 Jan; 5(1):95-100. PubMed ID: 18066073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
    Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
    J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 5' splice site enhances the recruitment of basal transcription initiation factors in vivo.
    Damgaard CK; Kahns S; Lykke-Andersen S; Nielsen AL; Jensen TH; Kjems J
    Mol Cell; 2008 Feb; 29(2):271-8. PubMed ID: 18243121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of zebrafish fgf8 pre-mRNA splicing with morpholino oligos: a quantifiable method for gene knockdown.
    Draper BW; Morcos PA; Kimmel CB
    Genesis; 2001 Jul; 30(3):154-6. PubMed ID: 11477696
    [No Abstract]   [Full Text] [Related]  

  • 10. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
    Davis RL; Homer VM; George PM; Brennan SO
    Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making antisense of splicing.
    Garcia-Blanco MA
    Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo.
    Li YF; Morcos PA
    Bioconjug Chem; 2008 Jul; 19(7):1464-70. PubMed ID: 18564870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morpholino antisense oligo inhibits trans-splicing of pre-inositol 1,4,5-trisphosphate receptor mRNA of Trypanosoma cruzi and suppresses parasite growth and infectivity.
    Hashimoto M; Nara T; Mita T; Mikoshiba K
    Parasitol Int; 2016 Jun; 65(3):175-9. PubMed ID: 26680159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
    Liu Y; Franzen S
    Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A generalizable strategy for imaging pre-mRNA levels in living subjects using spliceosome-mediated RNA trans-splicing.
    Walls ZF; Puttaraju M; Temple GF; Gambhir SS
    J Nucl Med; 2008 Jul; 49(7):1146-54. PubMed ID: 18552150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can donor splice site recognition occur without the involvement of U1 snRNP?
    Raponi M; Baralle D
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):548-50. PubMed ID: 18482005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia.
    Vega AI; Pérez-Cerdá C; Desviat LR; Matthijs G; Ugarte M; Pérez B
    Hum Mutat; 2009 May; 30(5):795-803. PubMed ID: 19235233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of Snu114p during pre-mRNA splicing.
    Frazer LN; Nancollis V; O'Keefe RT
    Biochem Soc Trans; 2008 Jun; 36(Pt 3):551-3. PubMed ID: 18482006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of PepFect peptides for the delivery of splice-correcting oligonucleotides.
    Andaloussi SE; Lehto T; Lundin P; Langel U
    Methods Mol Biol; 2011; 683():361-73. PubMed ID: 21053143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splice-switching antisense oligonucleotides as therapeutic drugs.
    Havens MA; Hastings ML
    Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.